Catabasis Pharmaceuticals, a Cambridge, Mass.-based biopharmaceutical company developing novel therapeutics for the treatment of inflammatory and metabolic diseases, has completed a $39.6m Series A financing.
The round was led led by SV Life Sciences, Clarus Ventures, and MedImmune Ventures. Also participating in the financing is Advanced Technology Ventures.
The capital infusion will be used to advance the company’s lead program targeting type 2 diabetes, and to further the development of its proprietary platform technology in additional inflammatory and metabolic diseases.
Catabasis was founded in 2008 by two experienced executives and drug developers Jill Milne, Ph.D., Catabasis’ chief executive officer, and Mike Jirousek, Ph.D., Catabasis’ chief scientific officer, as well as Steven Shoelson, M.D., Ph.D., Harvard Medical School and Joslin Diabetes Center, on an approach that focuses on targeting inflammation to treat complex human diseases.